The Global Cardiac Arrest Treatment Market is estimated to be USD 17.63 Bn in 2021 and is expected to reach USD 27.39 Bn by 2026, growing at a CAGR of 9.21%.
Huge investments in research and development associated with cardiac arrest treatment are expected to foster new opportunities for the market during the forecast period.
By Treatment, the market is classified as Drugs and Medical Devices. Amongst the two, the Medical Devices segment is estimated to hold the highest market share during the forecast period.
By Distribution Channel, the market is classified as Hospitals, Retail Pharmacies, Online Pharmacies, and Others. Amongst all, the Hospitals segment is estimated to hold the highest market share during the forecast period.
By Geography, North America is projected to lead the market.
Market Dynamics
The major factor raising the global cardiac arrest treatment market is an increase in cardiovascular disorders (CVDs). The increasingly sedentary lifestyle, high alcohol & tobacco consumption, and rising geriatric population are leading to the increase in CVDs. Furthermore, increasing awareness of cardiac resynchronization therapy devices among the population is escalating the market growth. However, frequent product calls and the high cost of Treatment are anticipated to hinder the market during the forecast period.Huge investments in research and development associated with cardiac arrest treatment are expected to foster new opportunities for the market during the forecast period.
Market Segmentation
The Global Cardiac Arrest Treatment Market is segmented further based on Treatment, Distribution Channel and Geography.By Treatment, the market is classified as Drugs and Medical Devices. Amongst the two, the Medical Devices segment is estimated to hold the highest market share during the forecast period.
By Distribution Channel, the market is classified as Hospitals, Retail Pharmacies, Online Pharmacies, and Others. Amongst all, the Hospitals segment is estimated to hold the highest market share during the forecast period.
By Geography, North America is projected to lead the market.
Recent Developments
1. Philips received FDA premarket approval for its HeartStart FR3 and HeartStart FRx automated external defibrillators. - 23rd June 2020Company Profiles
Some of the companies covered in this report are Medico S.p.A., Medtronic plc, Novartis AG, Neurescue, Nihon Kohden Corporation, Pfizer, etc.Competitive Quadrant
The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.Why buy this report?
- The report offers a comprehensive evaluation of the Global Cardiac Arrest Treatment Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
- The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
- The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
- The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
- The report also contains the competitive analysis using Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.
Report Highlights:
- A complete analysis of the market, including parent industry
- Important market dynamics and trends
- Market segmentation
- Historical, current, and projected size of the market based on value and volume
- Market shares and strategies of key players
- Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Cardiac Arrest Treatment Market
What is the estimated value of the Global Cardiac Arrest Treatment Market?
What is the growth rate of the Global Cardiac Arrest Treatment Market?
What is the forecasted size of the Global Cardiac Arrest Treatment Market?
Who are the key companies in the Global Cardiac Arrest Treatment Market?
Report Attribute | Details |
---|---|
No. of Pages | 171 |
Published | June 2021 |
Forecast Period | 2021 - 2026 |
Estimated Market Value ( USD
| USD 17630 Million |
Forecasted Market Value ( USD
| USD 27390 Million |
Compound Annual Growth Rate | 9.2% |
Regions Covered | Global |
No. of Companies Mentioned | 25 |
Table of Contents
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Influencers
5 Market Analysis
6 Global Cardiac Arrest Treatment Market, By Treatment
7 Global Cardiac Arrest Treatment Market, By Distribution Channel
8 Global Cardiac Arrest Treatment Market, By Geography
9 Competitive Landscape
10 Company Profiles
11 Appendix
Companies Mentioned
- Abbott Laboratories
- Amgen Inc
- Allergan
- Bayer AG
- Biotronik SE & Co. KG
- Boston Scientific Corporation
- Bristol Myers Squibb Company
- Fukuda Denshi Co, Ltd
- Koninklijke Philips N.V.
- LivaNova PLC
- Lepu Medical
- MicroPort Scientific Corporation
- Medico S.p.A.
- Medtronic plc
- Novartis AG
- Neurescue
- Nihon Kohden Corporation
- Osypka Medical
- Pfizer Inc
- Sanofi S.A.
- Shree Pacetronix Ltd
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Stryker Corporation
- Viatris Inc
- ZOLL Medical Corporation